acute cutaneous lupus erythematosus - HEALTHIES
Patients with cutaneous lupus erythematosus (CLE) experienced improved symptoms with iberdomide, a cereblon modulator, added to standard lupus medications, particularly in subacute and chronic cases. ... Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement.
Understanding the Context
The cutaneous lesions, which range from a malar rash to more indurated, ... MedPage Today: Promising Therapeutic Developments for Cutaneous Lupus Erythematosus: Interfering With Interferon Disfigurement due to scars and dyspigmentation complicating discoid lupus erythematosus (DLE) can be devastating. The cornerstones of therapy for cutaneous lupus erythematosus (CLE) are steroids ... Medical Xpress: Skin and Connective Tissue Diseases: News and Research on Lupus Erythematosus, Cutaneous Skin and Connective Tissue Diseases: News and Research on Lupus Erythematosus, Cutaneous Nasdaq: Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy ...
Image Gallery
Key Insights
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting MarketWatch: Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus Newswire: Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus